ArticleFrontiers in neurology2025
Clinical implications and prognostic value of mastoid effusion in the management of aneurysmal subarachnoid hemorrhage.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impaired Glymphatic-Meningeal Lymphatic Function in Patients with Spontaneous Subarachnoid Hemorrhage.Translational stroke research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical significance of mastoid effusion (ME) in intensive care unit (ICU) patients has not been well elucidated. Recently, an association between ME and intracranial pressure (ICP) has been reported. We aimed to investigate the clinical implications of ME occurrence in the management of aneurysmal subarachnoid hemorrhage (aSAH) patients and its association with their prognosis. Methods: Data from patients aged > 18 years who were treated for aSAH in a single institution between January 2020 and December 2022 were retrospectively reviewed. Brain CT or MRI images obtained within the first 14 days after the onset of SAH were evaluated for the presence of ME, which is defined as either opacification or an air-fluid level in the mastoid air cells. We examined the patients' demographic information, neurological and medical status at admission, aneurysm and treatment characteristics, and clinical outcomes. We then analyzed how these factors were associated with the occurrence of ME. Results: A total of 114 patients were included in the study. ME was observed in 40 patients (34.5%) within the first 14 days, occurring at a mean of 5.0 ± 3.5 days after the onset of SAH. In multivariate analysis, patients with ME were found to have a higher incidence of tracheostomy (odds ratio [OR] 10.034, Conclusion: This study demonstrated that ME was observed in 34.5% of aSAH patients and was associated with poor clinical outcomes. ME may serve as a simple and useful prognostic indicator for predicting poor outcomes in aSAH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.